Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, AbCellera Biologics Inc’s stock clocked out at $4.87, down -9.31% from its previous closing price of $5.37. In other words, the price has decreased by -$9.31 from its previous closing price. On the day, 4.46 million shares were traded. ABCL stock price reached its highest trading level at $5.245 during the session, while it also had its lowest trading level at $4.86.
Ratios:
To gain a deeper understanding of ABCL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.07 and its Current Ratio is at 11.07. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.14.
The Benchmark Company Upgraded its Hold to Buy on February 22, 2024, while the target price for the stock was maintained at $9.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1455316352 and an Enterprise Value of 1044318272. For the stock, the TTM Price-to-Sale (P/S) ratio is 44.26 while its Price-to-Book (P/B) ratio in mrq is 1.44. Its current Enterprise Value per Revenue stands at 31.765 whereas that against EBITDA is -4.782.
Stock Price History:
The Beta on a monthly basis for ABCL is 0.70, which has changed by 0.9456521 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, ABCL has reached a high of $6.51, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -4.31%, while the 200-Day Moving Average is calculated to be 35.76%.
Shares Statistics:
It appears that ABCL traded 5.10M shares on average per day over the past three months and 3725770 shares per day over the past ten days. A total of 298.65M shares are outstanding, with a floating share count of 225.43M. Insiders hold about 24.56% of the company’s shares, while institutions hold 35.62% stake in the company. Shares short for ABCL as of 1760486400 were 53201052 with a Short Ratio of 10.43, compared to 1757894400 on 44375292. Therefore, it implies a Short% of Shares Outstanding of 53201052 and a Short% of Float of 23.1.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of AbCellera Biologics Inc (ABCL).The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.14 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.55 and -$0.65 for the fiscal current year, implying an average EPS of -$0.6. EPS for the following year is -$0.5, with 4.0 analysts recommending between -$0.21 and -$0.83.
Revenue Estimates
In. The current quarter, 9 analysts expect revenue to total $6.33M. It ranges from a high estimate of $9.72M to a low estimate of $4.67M. As of. The current estimate, AbCellera Biologics Inc’s year-ago sales were $6.51MFor the next quarter, 9 analysts are estimating revenue of $6.87M. There is a high estimate of $11.24M for the next quarter, whereas the lowest estimate is $4.75M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $42.28M, while the lowest revenue estimate was $30.68M, resulting in an average revenue estimate of $34.09M. In the same quarter a year ago, actual revenue was $28.83MBased on 8 analysts’ estimates, the company’s revenue will be $69.21M in the next fiscal year. The high estimate is $176.53M and the low estimate is $29.04M.
